LRMR Earnings Larimar Therapeutics, Inc.
Reported diluted EPS by fiscal period (SEC EDGAR). Chart & overview →
1–20 of 20
| Q3 2025 | 2025-09-30 | -1.50 | 2025-11-05 | 10-Q |
| Q2 2025 | 2025-06-30 | -0.87 | 2025-08-14 | 10-Q |
| Q1 2025 | 2025-03-31 | -0.46 | 2025-04-30 | 10-Q |
| FY 2024 | 2024-12-31 | -1.32 | 2025-03-24 | 10-K |
| Q3 2025 | 2024-09-30 | -0.86 | 2025-11-05 | 10-Q |
| Q2 2025 | 2024-06-30 | -0.62 | 2025-08-14 | 10-Q |
| Q1 2025 | 2024-03-31 | -0.27 | 2025-04-30 | 10-Q |
| FY 2024 | 2023-12-31 | -0.84 | 2025-03-24 | 10-K |
| Q3 2024 | 2023-09-30 | -0.55 | 2024-10-30 | 10-Q |
| Q2 2024 | 2023-06-30 | -0.34 | 2024-08-08 | 10-Q |
| Q1 2024 | 2023-03-31 | -0.15 | 2024-05-09 | 10-Q |
| FY 2023 | 2022-12-31 | -1.37 | 2024-03-14 | 10-K |
| Q3 2023 | 2022-09-30 | -1.32 | 2023-11-14 | 10-Q |
| Q2 2023 | 2022-06-30 | -0.96 | 2023-08-10 | 10-Q |
| Q1 2023 | 2022-03-31 | -0.49 | 2023-05-15 | 10-Q |
| FY 2022 | 2021-12-31 | -2.95 | 2023-03-14 | 10-K |
| Q3 2022 | 2021-09-30 | -2.48 | 2022-11-10 | 10-Q |
| Q2 2022 | 2021-06-30 | -1.54 | 2022-08-11 | 10-Q |
| Q1 2022 | 2021-03-31 | -0.76 | 2022-05-12 | 10-Q |
| FY 2021 | 2020-12-31 | -3.57 | 2022-03-25 | 10-K |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Informational only — not financial advice.